ReviewMolecular and cellular biochemistry2026
Cell death forms in myocardial ischemia-reperfusion injury and their potential clinical applications.
Review in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Enhancement of content, purity and anti-myocardial ischemia-reperfusion injury activity of persimmon leaf flavonoids: Ultrasonic-assisted extraction, purification and related mechanism.Ultrasonics sonochemistry · 2026Article
- Valsartan Reduces Myocardial Ischemia-Reperfusion Injury by Inhibiting Ferritinophagy-Mediated Ferroptosis.Journal of cellular and molecular medicine · 2026Article
- Dose- and time-dependent cardioprotection of liproxstatin-1 via sequential modulation of ferroptosis pathways after myocardial ischemia-reperfusion.Molecular and cellular biochemistry · 2026Article
- [Growth differentiation factor 11 attenuates hypoxia/reoxygenation injury in rat H9C2 cardiomyocytesNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Timely and effective reperfusion therapy is an effective means of relieving ischemic damage to cardiomyocytes and is also the most commonly used treatment for clinical ischemic heart disease. However, while reperfusion saves the ischemic myocardium, the explosive production of reactive oxygen species (ROS) and calcium overload can cause additional damage to cardiac tissue cells. This review describes the pathophysiological mechanisms of myocardial ischemia-reperfusion injury and the forms of myocardial tissue cell death mediated by the reperfusion process, including ferroptosis, pyroptosis, and necroptosis. We also report the latest research progress in treating myocardial reperfusion injury by targeting ferroptosis, pyroptosis, and necroptosis. The aim is to understand the mechanism of myocardial reperfusion injury better and provide new treatment ideas to reduce myocardial ischemia-reperfusion injury.
Indexed as
Identifiers
41252094What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.